More recently, the trifunctional antibody Catumaxomab, which targets EpCAM on epithelial cells and mitigates a multipronged, anti-cancer immune response [18], has been used in the treatment of malignant ascites in epithelial cancers. Here, EPCAM is linked to cancer.